Table 1 Clinical characteristics of the 65 patients in this study
Characteristic | Category | All patients (n=65) | nICT (n=26) | nCT (n=39) | P |
|---|---|---|---|---|---|
Age (years) | Median (range) | 67 (44–79) | 67 (44–79) | 67 (48–73) |  |
Sex | Â | Â | Â | Â | 1.000 |
| Â | Male | 54 (83.1%) | 22 (40.7%) | 32 (59.3%) | Â |
Female | 11 (16.9%) | 4 (36.4%) | 7 (63.6%) | Â | |
Location | Â | Â | Â | Â | 0.199 |
| Â | Proximal | 2 (3.1%) | 1 (50.0%) | 1 (50.0%) | Â |
Middle | 24 (36.9%) | 9 (37.5%) | 15 (62.5%) | Â | |
Distal | 34 (52.3%) | 16 (47.1%) | 18 (52.9%) | Â | |
Gastroesophageal junction | 5 (7.7%) | 0 (0.0%) | 5 (100.0%) | Â | |
Histology | Â | Â | Â | Â | 0.167 |
| Â | Squamous cell carcinoma | 57 (87.7%) | 25 (43.9%) | 32 (56.1%) | Â |
Adenocarcinoma | 5 (7.7%) | 0 (0.0%) | 5 (100.0%) | Â | |
Others | 3 (4.6%) | 1 (33.3%) | 2 (66.7%) | Â | |
c-TNM | Â | Â | Â | Â | 0.685 |
| Â | II | 33 (50.8%) | 14 (42.4%) | 19 (57.6%) | Â |
III | 32 (49.2%) | 12 (37.5%) | 20 (62.5%) | Â | |
Adjuvant therapy | Â | Â | Â | 0.079 | |
| Â | Yes | 39 (60.0%) | 19 (48.7%) | 20 (51.3%) | Â |
No | 26 (40.0%) | 7 (26.9%) | 19 (73.1%) | Â | |
Adjuvant chemotherapy | Â | Â | Â | 0.005 | |
| Â | Yes | 14 (21.5%) | 1 (7.1%) | 13 (92.9%) | Â |
No | 51 (78.5%) | 25 (49.0%) | 26 (51.0%) | Â | |
Adjuvant immunochemotherapy | Â | Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <0.001 | |||
| Â | Yes | 14 (21.5%) | 14 (100%) | 0 (0.0%) | Â |
No | 51 (78.5%) | 12 (23.5%) | 39 (76.5%) | Â | |
Adjuvant radiotherapy | Â | Â | Â | 1.000 | |
| Â | Yes | 11 (16.9%) | 4 (36.4%) | 7 (63.6%) | Â |
No | 54 (83.1%) | 22 (40.7%) | 32 (59.3%) | Â | |